Persistence of BCR/ABL mRNA-expressing bone-marrow cells in patients with chronic myelogenous leukemia in complete cytogenetic remission induced by interferon-alpha therapy

Leukemia & Lymphoma
F EberléP Mannoni

Abstract

Complete hematologic and cytogenetic responses can be obtained with interferon-alpha (IFN-alpha) in 15-25% of the patients with chronic myelogenous leukemia (CML). In these patients, reverse-transcription polymerase chain reaction (RT-PCR) can be used to evaluate minimal residual disease. We studied 12 patients who remained Philadelphia-negative for a median period of 21 months on IFN-alpha therapy. Using RT-PCR, the specific transcript was found in all bone marrow (BM) samples. Ten patients still exhibiting a persistent residual clone remained in cytogenetic remission for a median period of 14 months. As we observed a dissociation between bcr-abl expression in BM and peripheral blood (PB) cells, and given the known fluctuations of the bcr-abl PCR results, we suggest that PB negative results should be confirmed on BM specimens. Alternatively, it remains to be demonstrated whether longitudinal monitoring of residual disease would benefit from quantitative PCR or double fluorescence in situ hybridization.

References

May 18, 1989·Nature·S Kwok, R Higuchi
Oct 13, 1988·The New England Journal of Medicine·R KurzrockM Talpaz
Aug 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·E S KawasakiF P McCormick
Jan 1, 1993·Leukemia & Lymphoma·A KeatingJ Levy

❮ Previous
Next ❯

Citations

Aug 23, 2002·Leukemia Research·Anjali S Advani, Ann Marie Pendergast
Jan 27, 1998·Hematology/oncology Clinics of North America·C M Verfaillie
Sep 15, 2015·The Cochrane Database of Systematic Reviews·Yongjun WangCynthia H Seow
Nov 25, 2017·BMJ Case Reports·Rohan Chawla, Koushik Tripathy

❮ Previous
Next ❯

Related Concepts

Related Feeds

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.